"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved rucaparib (Rubraca) for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer

FDA Approved rucaparib (Rubraca) for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer

29 Jun 2018 8:48 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved rucaparib (Rubraca; Clovis Oncology), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software